Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05281601
Other study ID # D8850C00006
Secondary ID 2021-006056-13
Status Completed
Phase Phase 1
First received
Last updated
Start date March 21, 2022
Est. completion date April 16, 2024

Study information

Verified date May 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD7442 administered intramuscularly (IM) or intravenously (IV) in pediatric participants aged ≥ 29 weeks GA to < 18 years.


Description:

This is a Phase I, open-label, uncontrolled, multi-country, multi-center, single-dose study. Initially, 2 cohorts of participants will be enrolled: 1) participants who are severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) negative at screening and have not knowingly been exposed to a SARS-CoV-2 positive individual (pre-exposure prophylaxis); and 2) participants who are SARS-CoV-2 RT-PCR positive at screening and have mild to moderate COVID-19 symptoms. A third cohort might be added for the treatment of severe COVID-19. If included, this third cohort will include participants who are SARS-CoV-2 positive at screening and have severe COVID-19.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date April 16, 2024
Est. primary completion date April 16, 2024
Accepts healthy volunteers No
Gender All
Age group 0 Years to 17 Years
Eligibility Inclusion Criteria: - Participant must be aged = 29 weeks gestational age (GA) to < 18 years of age. - Participant must weigh a minimum of 1.5 kg. COHORT 1 - Increased risk of severe COVID-19 because of immunocompromised state or one or more comorbid conditions that increase the risk of severe COVID-19. - Increased risk for SARS-CoV-2 infection. - Medically stable (disease not requiring significant change in therapy or hospitalization for worsening disease during the one month prior to enrollment). - A negative RT-PCR test collected = 3 days prior to Day 1 or a negative rapid SARS-CoV-2 antigen test at screening. - No COVID-19 symptoms prior to enrollment within 10 days of dosing. - Increased risk for SARS-CoV-2 infection. COHORT 2 - Increased risk of severe COVID-19 because of immunocompromised state or one or more comorbid conditions that increase the risk of severe COVID-19. - Medically stable (disease not requiring significant change in therapy or hospitalization for worsening disease during the one month prior to enrollment). - A positive RT-PCR test collected = 3 days prior to Day 1 or a positive rapid SARS-CoV-2 antigen test at screening. - Symptomatic participants must be dosed with IMP no more than 7 days from the self-reported date of first reported sign/symptom. - Oxygenation saturation of = 92% obtained at rest within 24 hours prior to Day 1 unless the potential participant regularly receives chronic supplementary oxygen for an underlying lung condition. Note that Cohort 2 will only be included if the indication is progressed in adults. COHORT 3 - Participants hospitalized with COVID-19 with a time between onset of symptoms and dosing AZD7442 of = 7 days. - A positive RT-PCR test collected = 3 days before Day 1 or a positive rapid SARS-CoV-2 antigen test at screening. - Spontaneous blood Alanine Aminotransferase (ALT)/Aspartate Transaminase (AST) levels = 5 times the ULN. - Glomerular Filtration Rate (GFR) = 30 mL/min/1.73 m2. Participants will receive IM AZD7442 unless they meet any of the following criteria for IV administration: - The participant has severe COVID-19. - Contraindication of intramuscular (IM) dose due to thrombocytopenia, coagulation defects or any other condition that would compromise the absorption of AZD7442 or safety of the participant. - Physician considers IV the appropriate route. Exclusion Criteria: All Cohorts - Cohort 1: Significant infection or other acute illnesses including fever on or the day prior to receiving AZD7442. - History of SARS-CoV-1 or Middle East Respiratory Syndrome Coronavirus (MERS-CoV). - Cohorts 1 and 2: Current need for immediate medical attention or current need for hospitalization. - Mechanical ventilation or extracorporeal membrane oxygenation requirement for COVID-19. - History of allergic or reaction to any component of the study drug formulation. - History of hypersensitivity, injection/infusion-relation reactions or severe adverse reactions following administration of a monoclonal antibody (mAb). - Co-morbidity requiring surgery within 7 days prior to study entry or is deemed life-threatening within 30 days prior to study entry. - Prior receipt of convalescent COVID-19 plasma/sera or hyperimmune globulin therapy. - Prior receipt of mAb/biologic indicated for the prevention of SARS-CoV-2, treatment of COVID-19, or expected receipt during the period of study follow-up. - Prior receipt of a COVID-19 vaccine = 14 days before screening or plan to receive a COVID-19 vaccination = 14 days after IMP administration at study Visit 1. - History of alcohol or drug abuse within the past 2 years. - Investigational Drugs or Devices: Treatment with investigational drug or device in another clinical trial within the last 30 days or 5 half-lives of the drug (whichever is longer) prior to screening. Note: Participation in observational studies (ie, studies that do not require medication, blood draws, or an additional intervention) is not exclusionary. Interventional trials which do not include investigational drugs (only include approved therapies), or investigational treatment regimens may be considered if the blood draw requirements and study interventions are minimal and not deemed by the Investigator to interfere with completion of the planned study sampling and follow-up. - Vulnerable persons (eg, ward of the state, kept in detention).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AZD7442
IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order. IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion.

Locations

Country Name City State
Belgium Research Site Leuven
Brazil Research Site Belo Horizonte
Brazil Research Site Porto Alegre
Germany Research Site Frankfurt am Main
United Kingdom Research Site Southampton
United States Research Site Aurora Colorado
United States Research Site Idaho Falls Idaho
United States Research Site Long Beach California
United States Research Site Mount Pleasant South Carolina
United States Research Site Providence Rhode Island
United States Research Site Stony Brook New York
United States Research Site Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Belgium,  Brazil,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Nasal concentrations of AZD7442 at specified time points during the study period when administered as a single IM or IV dose The concentration of AZD7442 in nasal fluid after a single dose in pediatric participants will be evaluated. Post Day 1 to Day 366
Primary Serum concentrations of AZD7442 The serum concentrations of AZD7442 after a single IM or IV dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Maximum serum concentration (Cmax) The Cmax of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Time to reach maximum serum concentration (tmax) The tmax of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Terminal half-life (t1/2) The t1/2 of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Area under the serum concentration versus time curve from time zero to time of last measurable concentration (AUC0-last) The AUC0-last of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Area under the serum concentration versus time curve extrapolated to infinity (AUC0-inf) The AUC0-inf of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Time to last measurable concentration (tlast) The tlast of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Percentage of AUC0-inf extrapolated to infinity (% AUCex) The %AUCex of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Apparent total clearance (CL/F) The CL/F of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Apparent volume of distribution based on terminal phase (Vz/F) The Vz/F of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Systemic clearance (CL) The CL of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Volume of distribution at steady state (Vss) The Vss of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Primary Model-derived predicted serum AZD7442 concentrations The serum concentrations of AZD7442 after a single dose in pediatric participants will be model-derived. Day 1 to Day 366
Primary Model-derived predicted AUC0-inf The AUC0-inf of AZD7442 after a single dose in pediatric participants will be model-derived. Day 1 to Day 366
Primary Number of participants with adverse events (Treatment Emergent Adverse Events [TEAEs], Serious Adverse Events [SAEs], and Adverse Event of Special Interests [AESIs]) The safety and tolerability of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 457 (upto 15 months)
Secondary All Cohorts (Other than Neonates) Titer of SARS-CoV-2 neutralizing antibodies (nAb) The PD of AZD7442 after a single dose in pediatric participants will be evaluated. Day 1 to Day 366
Secondary All Cohorts (Other than Neonates) - Number of participants with positive/negative antidrug antibodies (ADA) result and nAb to AZD7442. The immunogenicity profile of AZD7442 after a single dose in pediatric participants will be evaluated. Number of participants with positive/negative ADA result and nAb to AZD7442 will be evaluated. Day 1 to Day 366
Secondary Cohort 1 (Prophylaxis) - Incidence of SARS-CoV-2 infections The incidence of SARS-CoV-2 infections with or without COVID-19 symptoms after a single dose of AZD7442 in pediatric participants will be evaluated. Day 1 to Day 366
Secondary Cohort 2 and Cohort 3 (Treatment) - Change from baseline to Day 8 in viral load The SARS-CoV-2 viral loads measured by qRT-PCR after a single dose of AZD7442 in pediatric participants will be evaluated. Baseline, Day 8
Secondary Cohort 2 and Cohort 3 (Treatment) - Proportion of participants with progression of COVID-19 The percentage of participants with progression of COVID-19 after a single dose of AZD7442 in pediatric participants will be evaluated. Day 1 to Day 29
Secondary Cohort 2 and Cohort 3 (Treatment) - The incidence of COVID-19-related death occurring after dosing with IMP through 90 days COVID-19-related death after a single dose of AZD7442 in pediatric participants will be evaluated. Day 1 to Day 90
Secondary Cohort 3 (Severe COVID-19) - Time to sustained recovery The time to sustained recovery from severe COVID-19 after a single dose of AZD7442 in pediatric participants will be evaluated. Day 1 to Day 366 (from the index hospitalization followed by being alive and home for 14 consecutive days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A